The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mukund Kakani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mukund Kakani, a promoter of Godavari Drugs Limited, acquired 4,69,000 convertible warrants through a preferential issue on 18 March 2026. Before this acquisition, he held 3,50,000 equity shares representing 4.65% of the company's voting capital. After the warrant acquisition, his total potential holding rises to 8,19,000 units, equating to 4.65% of total share capital and 6.56% on a fully diluted basis (which assumes all warrants are converted into equity shares). The company's equity share capital expanded from 75,30,500 shares (Rs. 7.53 crore) to 1,01,27,435 shares (Rs. 10.13 crore) following this and related allotments, with total diluted capital standing at 1,24,87,500 shares.
This is a confidence-building signal as a promoter is increasing his potential stake in the company through a preferential warrant allotment. However, it also means dilution for existing shareholders once the warrants are converted. Short-term stock impact may be modestly positive reflecting promoter commitment, though the actual conversion and any further stake buildup will be key to watch.